Skip to main content
Premium Trial:

Request an Annual Quote

Ambion: Aug 21, 2008

Ambion, a unit of Applied Biosystems, has recently introduced a new Anti-miR microRNA inhibitor positive control for hsa-let-7c.
According to the company, the validated positive control can be monitored in human or mouse cells by qRT-PCR using a TaqMan gene expression assay to HGMA2.
Ambion has also released sets of its Silencer Select siRNAs targeting the human druggable genome in sets grouped by gene target class. The siRNAs are available in a ready-to-ship 0.25 nanomolar format or in larger customer quantities.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.